Compare Globus Medical Inc. Class A Common Stock (GMED) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.78 (market cap $44.60B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 4.4× Globus Medical Inc. Class A Common Stock's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and JPMorgan Nasdaq Equity Premium Income ETF for 67 Days on average.
| GMED | JEPQ | |
|---|---|---|
Market Cap | $10.25B | $44.60B |
Volume | 1,108,124 | 3,957,816 |
Sector | Health | Income / Options Overlay |
52-Week High | $96.82 | $61.46 |
52-Week Low | $58.33 | $53.77 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
JEPQ trades at $60.92, showing minimal daily movement with a neutral technical signal. The ETF maintains a covered-call strategy focused on Nasdaq exposure, generating monthly income through dividends. Recent distributions have shown variability, with payouts ranging from $0.57 to $0.70 per share. Moving averages indicate bullish momentum while oscillators remain neutral, suggesting balanced near-term positioning.
The ETF offers high-yield income potential with an estimated 11% annualized yield, though price appreciation may be limited by the covered-call strategy. Key risks include market volatility dependence and potential tax implications from return of capital. Institutional interest remains strong, with recent acquisitions signaling confidence in the income strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
